معرفی
Andreas Vogt is an Associate Professor of Computational and Systems Biology at the University of Pittsburgh Drug Discovery Institute (UPDDI). He focuses on expanding high-content screening (HCS) methodologies to multicellular organisms like zebrafish, C. elegans, and Drosophila for drug discovery in cancer immunology, organ regeneration, and neurodegenerative diseases. His work bridges cellular models with in vivo systems to improve therapeutic candidate identification.
Research Interests: Dr. Vogt pioneers HCS applications in zebrafish larvae for regenerative medicine, including kidney and heart regeneration (grants: R01HD053287, RC4DK090770, R01DK112652), vascular biology (American Heart Association 13GRNT16830049), and Parkinson’s disease. He develops platform-independent image analysis tools and collaborates with Neurology, Developmental Biology, and Public Health departments.
Technical Leadership: He directed the NIH-funded Pittsburgh Molecular Libraries Screening Center (HTS Core) and secured an Opera Phenix Plus high-content reader via NIH S10 OD025263. His team created assays like the ORIS™ cell motility platform and quantified reporter gene expression in zebrafish models.
Drug Discovery Translation: As a UPDDI leadership faculty member, he advises on target validation, assay development, and high-throughput screening to advance basic discoveries into therapeutics, with applications to NIH grants and funding agencies.
Academic Contributions: Dr. Vogt holds a PhD in Pharmaceutical Chemistry and a BS in Pharmacy from the University of Hamburg, Germany. He co-founded ProlX Pharmaceuticals (now Seattle Genetics) and contributed to 25+ NIH projects.
